The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Copy number analysis to identify tumor suppressor genes associated with enzalutamide (Enza) resistance and poor prognosis in metastatic castration-resistant prostate cancer (mCRPC) patients.
 
Xiangnan Guan
No Relationships to Disclose
 
Duan-Chen Sun
No Relationships to Disclose
 
Eric Lu
No Relationships to Disclose
 
Joshua A. Urrutia
No Relationships to Disclose
 
Robert Evan Reiter
Stock and Other Ownership Interests - ImaginAb
Consulting or Advisory Role - Astellas Pharma
Speakers' Bureau - Genomic Health; ImaginAb; Janssen Oncology
Patents, Royalties, Other Intellectual Property - patents surrounding discovery of PSCA and N-cadherin, owned by UCLA (Inst)
 
Matthew Rettig
No Relationships to Disclose
 
Christopher P. Evans
Stock and Other Ownership Interests - Exelixis
Honoraria - Janssen Oncology; Medivation; Sanofi
Consulting or Advisory Role - Astellas Pharma; Janssen Oncology; MDxHealth; Medivation; Sanofi
Speakers' Bureau - Astellas Pharma; Janssen Oncology; MDXHealth; Medivation; Sanofi
Research Funding - Astellas Pharma; Ferring; Medivation; Sanofi
Travel, Accommodations, Expenses - Astellas Pharma; Janssen Oncology; Sanofi
 
Primo Lara
Honoraria - Pfizer
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; CellMax Life; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Merck; Nektar; Pfizer; Turnstone Bio
Research Funding - Aragon Pharmaceuticals (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Heat Biologics (Inst); Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Polaris (Inst); TRACON Pharma (Inst)
 
Martin Gleave
Stock and Other Ownership Interests - OncoGenex
Honoraria - Abbvie; Amgen; Astellas Pharma; Bayer; Genova Diagnostics; Janssen; MDxHealth; Sanofi
Consulting or Advisory Role - Abbvie; Amgen; Astellas Pharma; AstraZeneca; Bayer; Genova Diagnostics; Janssen; MDxHealth; Sanofi
Research Funding - Astellas Pharma; Bayer; Janssen
Patents, Royalties, Other Intellectual Property - OncoGenex - OGX-011, OGX-427
 
Tomasz M. Beer
Stock and Other Ownership Interests - Salarius Pharmaceuticals
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Clovis Oncology; GlaxoSmithKline; Janssen; Janssen Biotech; Merck; Pfizer
Research Funding - Alliance Foundation Trials (Inst); Boehringer Ingelheim (Inst); Corcept Therapeutics (Inst); Janssen Research & Development (Inst); Medivation/Astellas (Inst); Oncogenex (Inst); Sotio; Sotio (Inst); Theraclone Sciences (Inst)
 
George V. Thomas
Consulting or Advisory Role - Auron Therapeutics
Patents, Royalties, Other Intellectual Property - Patensts t UCLA and OHSU (Inst)
 
Jiaoti Huang
No Relationships to Disclose
 
Zheng Xia
No Relationships to Disclose
 
Joshi J. Alumkal
Consulting or Advisory Role - Janssen Biotech
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Gilead Sciences (Inst); Novartis (Inst); Zenith Epigenetics (Inst)